Damoctocog Alfa Pegol

證據等級: L5

預測適應症: 0 個

Damoctocog Alfa Pegol: Evaluation Pending — No TxGNN Repurposing Predictions Available

Summary

Damoctocog alfa pegol (DrugBank ID: DB14700) is a PEGylated recombinant coagulation factor VIII biological product currently not marketed in Denmark. The TxGNN pipeline returned no repurposing candidates for this drug, and critical data items — including mechanism of action and safety profile — are absent from the current evidence pack. A full drug repurposing evaluation cannot be completed until these gaps are resolved.

Quick Overview

Item	Content
Original Indication	Not recorded in evidence pack
Predicted New Indication	None — TxGNN returned no candidates
TxGNN Prediction Score	N/A
Evidence Level	L5 (no predictions generated; evaluation not possible)
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why Were No Predictions Generated?

The query log confirms that the DrugBank lookup succeeded (DB14700, 1 result), meaning the drug identity was resolved. However, the prediction pipeline returned an empty candidate list. This typically occurs for one of three reasons:

Knowledge graph coverage gap: The TxGNN knowledge graph may not contain sufficient edges connecting damoctocog alfa pegol to disease nodes, because it is a large-molecule biological (PEGylated recombinant FVIII) rather than a small-molecule drug. TxGNN’s training data is weighted toward small molecules.
Missing indication seed: The original_indications field is empty, which means the pipeline had no approved indication anchor from which to calculate mechanistic similarity scores across disease space.
MOA data absent: Without a documented mechanism of action in the evidence pack, the model cannot leverage mechanism-based feature vectors to rank candidate indications.

Until the original indication and MOA are populated, no meaningful repurposing signal can be extracted from TxGNN for this compound.

Denmark Market Information

Damoctocog alfa pegol holds no marketing authorisations in Denmark, and is recorded as not marketed. No product entries are available from Lægemiddelstyrelsen or the centralised EMA register in this evidence pack.

Note for the reviewer: Damoctocog alfa pegol (brand name Jivi®, BAY 94-9027) has a centralised EMA Marketing Authorisation for prophylaxis and treatment of bleeding in adults with haemophilia A (congenital factor VIII deficiency). If this drug is intended for evaluation, the evidence pack data retrieval step should be repeated with an EMA-sourced licence lookup, as the current pack shows zero records — this is likely a retrieval gap rather than a true absence of authorisation.

Safety Considerations

No safety data were retrieved for this compound in the current evidence pack. Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence pack contains no TxGNN predictions, no original indication records, no mechanism of action, and no safety data — the minimum inputs required to generate or evaluate a repurposing hypothesis are all absent.

To proceed, the following is needed:

Resolve Blocking data gap (DG001): Retrieve the full SmPC from the EMA product page (EMEA/H/C/004178) to extract approved indication text, key warnings, and contraindications.
Resolve High-severity data gap (DG002): Query DrugBank for the documented MOA of DB14700 (recombinant factor VIII mechanism — replacement of deficient coagulation factor VIII).
Populate original_indications: Insert the approved EMA indication (haemophilia A) so the TxGNN pipeline has an anchor disease node.
Re-run the TxGNN prediction pipeline once the above three items are in place.
Verify EMA licence retrieval: Confirm that the Lægemiddelstyrelsen / EMA data connector is correctly querying centralised authorisations, as the 0-licence result appears inconsistent with the drug’s known approval status in Europe.

⚠️ Disclaimer: This report is for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.